Lenvatinib is independently associated with the reduced risk of progressive disease when compared to sorafenib in patients with advanced hepatocellular carcinoma
Kim, Soojin, Kim, Kyung Hyun, Kim, Beom Kyung, Park, Jun Yong, Ahn, Sang Hoon, Kim, Do Young, Kim, Seung UpJournal:
Journal of Gastroenterology and Hepatology
DOI:
10.1111/jgh.15355
Date:
November, 2020
File:
PDF, 900 KB
2020